Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 15
Abnormality of the Urinary System 29 6
Congenital Malformation of the Urinary System 73
Non-Neoplastic Urinary System Disorder 73
Non-Neoplastic Urinary Tract Disease 12
Urinary Tract Diseases 55
Urinary Tract Disease 12
Urinary Tract Anomaly 55
Urologic Diseases 73

Classifications:



External Ids:

Disease Ontology 12 DOID:18
NCIt 50 C27599
ICD10 33 N39 N39.8

Summaries for Urinary System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as abnormality of the urinary system, is related to bladder disease and kidney disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways is Osteoblast Signaling. The drugs Zinc and Triamterene have been mentioned in the context of this disorder. Affiliated tissues include kidney, kidney and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 bladder disease 32.8 CRP KLK3 TRPV1
2 kidney disease 30.5 ACE ALB B2M CD79A CRP CST3
3 congenital anomalies of kidney and urinary tract 2 11.4
4 hyporeninemic hypoaldosteronism 11.3 ACE REN
5 cork-handlers' disease 11.2 ALB CD79A
6 ostertagiasis 11.2 ALB CD79A
7 diffuse glomerulonephritis 11.2 ALB B2M CD79A
8 dermatitis, atopic, 3 11.2 ALB CD79A
9 non-secretory myeloma 11.2 ALB B2M CD79A
10 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 11.2 NPHS1 NPHS2
11 renal artery obstruction 11.2 ACE REN
12 anuria 11.2 ACE ALB REN
13 chronic pyelonephritis 11.2 B2M PKDREJ UMOD
14 hypertensive nephropathy 11.2 ACE ALB NAGLU
15 autoimmune disease of urogenital tract 11.2 ALB CD79A TLR9
16 mature b-cell neoplasm 11.2 B2M CD79A TLR9
17 immunodeficiency 43 11.2 ALB B2M
18 uremic neuropathy 11.2 B2M EPO PTH
19 renal tuberculosis 11.2 B2M PKDREJ REN
20 hypertensive encephalopathy 11.2 ACE EPO REN
21 keratoconjunctivitis sicca 11.2 ALB CD79A TLR9
22 renal artery disease 11.2 ACE EPO REN
23 hypersensitivity reaction type iv disease 11.2 ACE CD79A TLR9
24 hydronephrosis 11.2 ALB B2M NAGLU
25 amyloid tumor 11.2 B2M CD79A PKDREJ
26 benign essential hypertension 11.2 ALB REN
27 nose disease 11.2 CD79A TLR9 TRPV1
28 human immunodeficiency virus infectious disease 11.2 B2M CD79A TLR9
29 hemorrhagic fever with renal syndrome 11.2 ALB B2M CRP
30 pure autonomic failure 11.1 ACE EPO REN
31 stomach disease 11.1 CD79A TLR9 TRPV1
32 acute cystitis 11.1 ALB CRP KLK3
33 parasitic helminthiasis infectious disease 11.1 CD79A TLR9 TRPV1
34 upper respiratory tract disease 11.1 CD79A TLR9 TRPV1
35 seminal vesicle adenocarcinoma 11.1 KLK3 KRT20
36 sclerosing keratitis 11.1 B2M CD79A
37 kidney hypertrophy 11.1 ALB NPHS1 NPHS2
38 hypersensitivity reaction type iii disease 11.1 ALB CD79A CRP
39 vesicoureteral reflux 1 11.1 NAGLU REN UMOD
40 acute pyelonephritis 11.1 ALB CRP NAGLU
41 membranoproliferative glomerulonephritis 11.1 ALB CD79A NPHS1
42 meningoencephalitis 11.1 ALB B2M CD79A TLR9
43 obstructive jaundice 11.1 ALB CD79A REN
44 dysentery 11.1 ALB CD79A CRP
45 reproductive system disease 11.1 KLK3 TLR9 TRPV1
46 exanthem 11.1 CD79A CRP TLR9
47 substernal goiter 11.1 CD79A PTH
48 mineral metabolism disease 11.1 FGF23 PTH REN
49 intermittent claudication 11.1 ACE ALB CRP
50 acute kidney failure 11.1 ALB B2M CST3 REN

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:


dysuria, polyuria, urgency of micturition, pain in urethra, renal colic, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, uti symptoms, bladder discomfort, renal pain, other and unspecified genitourinary symptoms, urologic problem

MGI Mouse Phenotypes related to Urinary System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 PTH CST3 EPO ACE FGF23 ALB
2 cardiovascular system MP:0005385 10.18 CRP PTH CST3 EPO ACE FGF23
3 hematopoietic system MP:0005397 10.07 EPO ACE FGF23 B2M NAGLU CD79A
4 immune system MP:0005387 10.07 CRP PTH EPO ACE FGF23 B2M
5 mortality/aging MP:0010768 9.77 NPHS2 CST3 EPO ACE ALB FGF23
6 liver/biliary system MP:0005370 9.7 EPO ACE ALB B2M NAGLU CD79A
7 renal/urinary system MP:0005367 9.4 ACE FGF23 ALB NAGLU CD79A NPHS1

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1520)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
2
Triamterene Approved Phase 4,Not Applicable 396-01-0 5546
3
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
4
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1952-01-7, 52-01-7 5833
5
Tazobactam Approved Phase 4,Phase 2,Phase 3,Phase 1 89786-04-9 123630
6
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
7
Etomidate Approved Phase 4 33125-97-2 36339 667484
8
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
10
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
11
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
12
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2 118-42-3 3652
13
Cloxacillin Approved, Investigational, Vet_approved Phase 4 61-72-3 6098
14
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
15
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216503-57-0
16
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-31-9 3440
17
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
18
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
19
Ertapenem Approved, Investigational Phase 4,Phase 3,Phase 2 153832-46-3 150610
20
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
21
Ampicillin Approved, Vet_approved Phase 4,Not Applicable 69-53-4 6249
22
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 15663-27-1 84093 441203 2767
23
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 7782-49-2
24
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
25
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
26
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
27
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
28
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
29
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
30
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
31
Amiloride Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 2016-88-8, 2609-46-3 16231
32
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
33
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
34
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
35
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1 81-81-2 6691 54678486
36
Nafamostat Approved, Investigational Phase 4,Phase 3 81525-10-2
37
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
38
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
39
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Not Applicable 128-13-2 31401
40
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52757-95-6
41
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
42
Deferiprone Approved Phase 4,Phase 3,Phase 2 30652-11-0 2972
43
Ezetimibe Approved Phase 4,Phase 1,Not Applicable 163222-33-1 150311
44
Chlorthalidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 77-36-1 2732
45
Midodrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
46
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
47
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
48
Doxazosin Approved Phase 4,Phase 3,Not Applicable 74191-85-8 3157
49
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
50
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 564-25-0 54671203

Interventional clinical trials:

(show top 50) (show all 9897)
# Name Status NCT ID Phase Drugs
1 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Cranberry for the Prevention of Urinary Tract Infections Unknown status NCT02454309 Phase 4
3 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Unknown status NCT02357758 Phase 4 Antibiotic Prophylaxis
4 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4 Advagraf
5 The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females Unknown status NCT02094703 Phase 4 Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
6 Gentamicin Bladder Instillation Trial Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
7 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
8 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
9 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
10 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
11 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
12 Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women Unknown status NCT00900653 Phase 4 Gynoflor E (low dose estriol with lactobacillus)
13 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4 Everolimus
14 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
15 Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) Unknown status NCT00290069 Phase 4 Tacrolimus;Rapamycin
16 Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
17 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
18 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
19 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
20 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
21 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
22 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
23 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
24 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
25 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
26 BIP Foley in Prevention of CAUTI at Rehab Station Unknown status NCT02808000 Phase 4
27 Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy Unknown status NCT02743156 Phase 4
28 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
29 Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg) Unknown status NCT02447822 Phase 4 Thymoglobulin
30 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4 IALURIL
31 Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD Unknown status NCT02302287 Phase 4
32 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
33 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
34 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
35 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
36 Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU Unknown status NCT01962116 Phase 4 Citrate 4%;unfractionated heparin
37 Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Unknown status NCT00889629 Phase 4 Doxercalciferol;placebo
38 Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis Unknown status NCT01860183 Phase 4 Mycophenolate mofetil
39 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
40 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
41 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
42 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
43 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
44 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
45 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
46 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
47 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
48 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
49 Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
50 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid

Search NIH Clinical Center for Urinary System Disease

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 29

Anatomical Context for Urinary System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary System Disease:

19
Kidney

MalaCards organs/tissues related to Urinary System Disease:

41
Kidney, Heart, Bone, Testes, Prostate, Liver, Endothelial

Publications for Urinary System Disease

Articles related to Urinary System Disease:

(show all 11)
# Title Authors Year
1
The association of pioglitazone and urinary tract disease in type 2 diabetic taiwanese: bladder cancer and chronic kidney disease. ( 24427312 )
2014
2
Occurrence of bacteriuria in 18 catheterised cats with obstructive lower urinary tract disease: a pilot study. ( 23400682 )
2013
3
Comparison of urine protein profiles in cats without urinary tract disease and cats with idiopathic cystitis, bacterial urinary tract infection, or urolithiasis. ( 21962285 )
2011
4
Epidemiologic approach for early detection and control of renal and urinary tract diseases in rural populations. ( 17580586 )
2007
5
Bacteriuria in cats with feline lower urinary tract disease: a clinical study of 134 cases in Norway. ( 17693110 )
2007
6
N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. ( 16622944 )
2005
7
Urinary tract diseases revealed after DTP vaccination in infants and young children: cytokine irregularities and down-regulation of cytochrome P-450 enzymes induced by the vaccine may uncover latent diseases in genetically predisposed subjects. ( 15356430 )
2004
8
[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. ( 12577571 )
2002
9
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases. ( 10550316 )
1999
10
Urinary beta-HCG in benign and malignant urinary tract diseases. ( 7542189 )
1995
11
Prevalence of symptomless urinary tract disease in Birmingham schoolchildren. I. Pyuria and bacteriuria. ( 5790270 )
1969

Variations for Urinary System Disease

ClinVar genetic disease variations for Urinary System Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;X;t(Y;3)(p11.2;p12.3)dn Translocation Likely pathogenic

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.77 FGF23 PTH

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 ACE ALB B2M CRP CST3 KLK3
2 extracellular region GO:0005576 9.73 ACE ALB B2M CRP CST3 EPO
3 endoplasmic reticulum lumen GO:0005788 9.67 ALB B2M CST3 FGF23
4 external side of plasma membrane GO:0009897 9.62 ACE B2M CD79A TRPV1
5 extracellular space GO:0005615 9.36 ACE ALB B2M CRP CST3 EPO
6 slit diaphragm GO:0036057 9.16 NPHS1 NPHS2

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.54 ACE REN SIX1
2 amyloid-beta metabolic process GO:0050435 9.32 ACE REN
3 response to molecule of bacterial origin GO:0002237 9.26 B2M TLR9
4 angiotensin maturation GO:0002003 9.16 ACE REN
5 excretion GO:0007588 9.13 NPHS1 NPHS2 UMOD
6 cellular protein metabolic process GO:0044267 9.02 ALB B2M CST3 FGF23 KLK3

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 ACE KLK3 REN

Sources for Urinary System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....